Skip to main content
SpringerLink
Log in

Diseases of the Liver

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Family Medicine

Abstract

Diseases of the liver encompass a wide variety of clinical conditions that range from mild abnormalities on liver testing to end-stage liver disease with intrahepatic and extrahepatic manifestations and complications. These also range from acute, self-limited presentations to fulminant disease with rapid liver failure to chronic, low-level disease and also to chronic liver disease that progresses slowly over time. While the history and physical signs of this broad range of clinical disorders are quite similar, often with nonspecific findings with broad-range differentials, laboratory evaluation is critical to sorting through these disease processes. It is critical for family physicians to have an understanding of liver pathology and the laboratory assessment of the hepatic system.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  2. Kojaoglanian T. Hepatitis A. Pediatr Rev. 2010;31(8):348–50. CrossRef PubMed

    PubMed  Google Scholar 

  3. Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician. 2012;86(11):1027–34. PubMed

    PubMed  Google Scholar 

  4. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59(8):2223–30. PubMed

    CAS  PubMed  Google Scholar 

  5. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1–37.

    Google Scholar 

  6. CDC. Updated recommendations from the ACIP for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR. 2009;58:1–36.

    Google Scholar 

  7. Doshani M, Weng M, Moore KL, Romero JR, Nelson NP. Recommendations of the Advisory Committee on Immunization Practices for the use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep. 2019;68:153–6.

    PubMed  PubMed Central  Google Scholar 

  8. Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: recommendations of the Advisory Committee on Immunization Practices for the use of hepatitis a vaccines for Postexposure prophylaxis and for Preexposure prophylaxis for international travel. MMWR Morb Moral Wkly Rep. 2018;67:1216–20.

    Google Scholar 

  9. Raimondo G, Pollicino T, Squadrito G. Clinical virology of hepatitis B virus infection. J Hepatol. 2003;39:S26–30. CrossRef PubMed

    PubMed  Google Scholar 

  10. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225–41. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  11. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–63.

    PubMed  Google Scholar 

  12. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.

    Google Scholar 

  13. Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev. 2012;2012(9):CD002799.

    PubMed Central  Google Scholar 

  14. Terrault NA, Lok A, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.

    PubMed  PubMed Central  Google Scholar 

  15. Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018;67(RR-1):1–31.

    PubMed  PubMed Central  Google Scholar 

  16. Gitnick G. Non-A, non-B hepatitis: etiology and clinical course. Annu Rev Med. 1984;35:265–78. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  17. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83. CrossRef PubMed PubMedCentral

    PubMed  PubMed Central  Google Scholar 

  18. Seef LB. Natural history of hepatitis C. Hepatology. 1997;26(Suppl 1):21S–8. CrossRef

    Google Scholar 

  19. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, del Valle Onorato M, Rodes J, Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995;21(3):639. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  20. Mitruka K, Thornton K, Cusick S, Centers for Disease Control and Prevention, et al. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based model – Arizona and Utah, 2012–2014. MMWR Morb Mortal Wkly Rep. 2014;63(18):393–8.

    PubMed  PubMed Central  Google Scholar 

  21. Tran TT. Hepatitis C: who should treat hepatitis C virus? The role of the primary care provider. Clin Liver Dis. 2018;11(3):66–8.

    Google Scholar 

  22. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.

    Google Scholar 

  23. Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58–67. CrossRef PubMed

    PubMed  Google Scholar 

  24. AASLD/ISDA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://​www.​hcvguidelines.​org. Accessed 20 Mar 2020.

  25. USPSTF. Screening for hepatitis C virus infection in adolescents and adults: US preventive services task force recommendation statement. JAMA. 2020;323(10):970–5.

    Google Scholar 

  26. National Institutes of Health. Management of hepatitis C: 2002. National Institutes of Health consensus conference statement. 10–12 June 2002. http://​consensus.​nih/​gov/​2002/​2002HepatitisC20​02116PDF.​pdf. Accessed 20 Mar 2020.

  27. Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics. 1998;101(3 Pt1):481–5.

    Google Scholar 

  28. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut. 1997;41:845–50. CrossRef PubMed PubMedCentral

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Cohen SM, Ahn J. Review article: the diagnosis and management of alcoholic hepatitis. Aliment Pharmacol Ther. 2009;30(1):3–13. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  30. Dugum MF, McCullough AJ. Acute alcoholic hepatitis, the clinical aspects. Clin Liver Dis. 2016;20(3):499–508.

    PubMed  PubMed Central  Google Scholar 

  31. Yamini D, Lee SH, Avanesyan A, Walter M, Runyon B. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol. 2014;49:453–6.

    CAS  PubMed  Google Scholar 

  32. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306–33.

    PubMed  Google Scholar 

  33. Moyer VA, Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(3):210–8. PubMed

    PubMed  Google Scholar 

  34. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38(Suppl 2):S44–8. CrossRef PubMed

    PubMed  Google Scholar 

  35. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24:483–90. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  36. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41. CrossRef PubMed

    PubMed  Google Scholar 

  37. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–8.

    CAS  PubMed  Google Scholar 

  38. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209. CrossRef PubMed

    PubMed  Google Scholar 

  39. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C coinfection. Clin Infect Dis. 2005;40:588–93. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  40. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13. CrossRef PubMed

    PubMed  Google Scholar 

  41. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464–73. CrossRef PubMed PubMedCentral

    PubMed  PubMed Central  Google Scholar 

  42. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  43. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.

    PubMed  Google Scholar 

  44. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: incidence – SEER 9 Regs research data, Nov 2009 Sub (1973–2007). Bethesda: National Cancer Institute; 2010 April.

    Google Scholar 

  45. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. CrossRef PubMed PubMedCentral

    PubMed  PubMed Central  Google Scholar 

  46. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  47. Lok AS, Sterling RK, Everhart JE, HALT-C Trial Group, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493–502. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  48. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36. CrossRef PubMed

    PubMed  Google Scholar 

  49. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74. CrossRef PubMed

    CAS  PubMed  Google Scholar 

  50. El Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63. CrossRef PubMed

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family and Community Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA

    David T. O’Gurek

Authors
  1. David T. O’Gurek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David T. O’Gurek .

Editor information

Editors and Affiliations

  1. Department of Family Medicine, University of Nebraska, Omaha, NE, USA

    Paul Paulman

  2. Department of Family and Community Medicine, Eastern Virginia Medical School, Norfolk, VA, USA

    Robert B. Taylor

  3. Department of Family Medicine, University of Nebraska Medical Center, Omaha, NE, USA

    Audrey A. Paulman

  4. Department of Family Medicine, Creighton University, Omaha, NE, USA

    Laeth S. Nasir

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media LLC

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

O’Gurek, D.T. (2020). Diseases of the Liver. In: Paulman, P., Taylor, R.B., Paulman, A.A., Nasir, L.S. (eds) Family Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0779-3_97-2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0779-3

  • Online ISBN: 978-1-4939-0779-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Diseases of the Liver
    Published:
    08 October 2020

    DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-2

  2. Original

    Diseases of the Liver
    Published:
    16 April 2015

    DOI: https://doi.org/10.1007/978-1-4939-0779-3_97-1

Search

Navigation